HK's Biostime to buy Australian vitamin maker Swisse for over US$1b: media
[SYDNEY] Hong Kong-listed dietary supplements company Biostime International Holdings has agreed to buy Australian vitamin maker Swisse Wellness for more than A$1.5 billion (S$1.5 billion), Australian media reported on Thursday.
The company beat Shanghai Pharmaceuticals Holding and Chinese private equity firm Hony Capital in a sale managed by Goldman Sachs Group Inc, the Australian newspaper and Fairfax Media said in reports, citing unnamed sources.
Swisse and Goldman Sachs were not immediately available for comment. Biostime issued a statement saying it had requested a trading halt for its shares, without giving an explanation.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices
Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too